Please check your internet connection and try again.
# Diloxanide Furoate
## Overview
Diloxanide furoate is a luminal amebicide that acts primarily within the intestinal lumen to kill *Entamoeba histolytica* cysts. It is poorly active against extraintestinal amebiasis. It is often used in combination with a systemic tissue amebicide (e.g., metronidazole) to clear residual luminal cysts after invasive infection treatment.
## Primary Indications
* Asymptomatic intestinal *E. histolytica* infection (cyst passers).
* Follow-up therapy for symptomatic amebiasis (after treatment with tissue-active agents like metronidazole or tinidazole).
## Adult Dosing
* **Standard dose:** 500 mg orally three times daily for 10 days.
## Pediatric Dosing
* **Standard dose:** 20 mg/kg/day orally, divided into three doses for 10 days.
* *Note:* Maximum daily dose should not exceed 1500 mg.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific guidelines exist; use with caution in severe hepatic impairment due to limited pharmacokinetic data. Consult local protocols if dosing in geriatric or multi-morbid patients.
## Contraindications
* Hypersensitivity to diloxanide furoate.
* Not recommended for the treatment of invasive amebiasis (e.g., amebic liver abscess) as monotherapy.
## Adverse Effects
* **Gastrointestinal:** Flatulence (highly common), abdominal cramps, nausea, and vomiting.
* **Systemic:** Pruritus, urticaria, and rarely, elevated liver enzymes.
## Key Drug Interactions
* Minimal systemic absorption limits significant drug-drug interactions. However, avoid concurrent use with other agents known to cause gastrointestinal toxicity, as additive effects may occur.
## Monitoring
* Monitor for resolution of gastrointestinal symptoms.
* If symptoms persist post-treatment, clear stool samples should be analyzed for *E. histolytica* to rule out treatment failure.
## Clinical Pearls
* **Efficacy:** It is highly effective against luminal disease but ineffective for invasive or extraintestinal amebiasis.
* **Administration:** Take doses consistently with meals to mitigate gastrointestinal side effects.
* **Availability:** In many regions, this medication is not commercially available and must be accessed through specialized travel clinics, public health departments, or international pharmacies (e.g., CDC Drug Service in the US).
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and clinical practices vary by institution and patient-specific factors. Always verify prescribing information through institutional formularies, local infectious disease guidelines, or the most current edition of the *CDC Yellow Book* or *Red Book* before administration.
